Passage Bio, Inc.(PASG)

Sector:

Healthcare

Description:

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Current Price

$0.96

RSI

38.70

Market Capitalization:

79.6M

Beta:

1.13

Volume:

165,781

Analyst Target Price:

$ 8.5

Economiic Fair Price:


November 02, 2022
November 10, 2022
Q3
N/A
N/A
N/A
N/A
N/A
62.6M
27.3M
-3.505
N/A
0
-0.546

$ -144.5M
-75.89 %
$ -82.2M
-97.57 %
$ -41.6M
-97.01 %
$ -21.1M

News

Press Releases

Notable Dates